Cyclosporin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilage

Arthritis Rheum. 2002 Jan;46(1):124-9. doi: 10.1002/1529-0131(200201)46:1<124::aid-art10121>;2-x.


Objective: To determine the effect of cyclosporin A (CSA) on aggrecanase- and matrix metalloproteinase (MMP)-mediated catabolism of proteoglycan (aggrecan) in articular cartilage explants stimulated with interleukin-1 (IL-1) in a culture system that mimics early pathologic processes associated with arthritic disease.

Methods: Proteoglycan (glycosaminoglycan) and lactate quantification, Western immunoblot analyses of aggrecan degradation products, reverse transcription-polymerase chain reaction analyses of aggrecanase-1, aggrecanase-2 (ADAM-TS4, ADAM-TS5, respectively), MMP-1, MMP-3, MMP-13, tissue inhibitor of metalloproteinases 1 (TIMP-1), TIMP-2, and TIMP-3 messenger RNA (mRNA) expression in articular cartilage explant cultures, and electrophoretic mobility shift assay analysis of nuclear factor of activated T cells (NF-AT) transcription factor activation were used.

Results: CSA inhibited, in a dose-dependent and noncytotoxic manner, aggrecanase-mediated proteoglycan catabolism and loss from IL-1-stimulated cartilage explants. There was no evidence of MMP-mediated aggrecan catabolism in this in vitro model. Treatment of articular cartilage explant cultures with 10 ng/ml of IL-1alpha up-regulated the expression of mRNA for ADAM-TS4, ADAM-TS5, MMP-1, MMP-3, and MMP-13. The expression of ADAM-TS4, ADAM-TS5, and MMP-13 was abrogated by the inclusion of 10 microM CSA in the culture medium. NF-AT activation was observed in chondrocytes but could not be inhibited by preincubation with 10 microM CSA.

Conclusion: CSA can inhibit IL-1-induced aggrecanase-mediated proteoglycan catabolism in articular cartilage explants maintained in culture for 4 days, thus demonstrating molecular mechanisms whereby CSA may be an effective therapy for degenerative joint disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aggrecans
  • Animals
  • Antirheumatic Agents / pharmacology*
  • Cartilage, Articular / cytology
  • Cartilage, Articular / metabolism*
  • Cattle
  • Cells, Cultured
  • Chondrocytes / cytology
  • Chondrocytes / enzymology
  • Cyclosporine / pharmacology*
  • DNA-Binding Proteins / metabolism
  • Dose-Response Relationship, Drug
  • Endopeptidases / genetics
  • Endopeptidases / metabolism*
  • Extracellular Matrix Proteins*
  • Gene Expression Regulation, Enzymologic / drug effects
  • Interleukin-1 / pharmacology
  • Joint Diseases / drug therapy
  • Joint Diseases / metabolism
  • Lectins, C-Type
  • Metalloendopeptidases / genetics
  • NFATC Transcription Factors
  • Nuclear Proteins*
  • Proteoglycans / metabolism*
  • Tissue Inhibitor of Metalloproteinases / genetics
  • Transcription Factors / metabolism


  • Aggrecans
  • Antirheumatic Agents
  • DNA-Binding Proteins
  • Extracellular Matrix Proteins
  • Interleukin-1
  • Lectins, C-Type
  • NFATC Transcription Factors
  • Nuclear Proteins
  • Proteoglycans
  • Tissue Inhibitor of Metalloproteinases
  • Transcription Factors
  • Cyclosporine
  • Endopeptidases
  • Metalloendopeptidases
  • aggrecanase